Cancer is associated with immune deficiency, but the biologic basis of this is poorly defined. Here we demonstrate that impaired actin polymerization results in CD4+ and CD8+ T cells from patients with chronic lymphocytic leukemia (CLL) exhibiting defective immunological synapse formation with APCs. Although this synapse dysfunction was in part a result of the CLL cells having poor APC function, defective actin polymerization was also identified in T cells from patients with CLL. We further demonstrate that, following contact with CLL cells, defects in immune synapse formation were induced in healthy allogeneic T cells. This required direct contact and was inhibited by blocking adhesion molecules on CLL B cells. In T cells from patients with CLL and in T cells from healthy individuals that had been in contact with CLL cells, recruitment of key regulatory proteins to the immune synapse was inhibited. Treatment of autologous T cells and CLL cells with the immunomodulating drug lenalidomide resulted in improved synapse formation. These results define what we believe to be a novel immune dysfunction in T cells from patients with CLL that has implications for both autologous and allogeneic immunotherapy approaches and identifies repair of immune synapse defects as an essential step in improving cancer immunotherapy approaches.
Alan G. Ramsay, Amy J. Johnson, Abigail M. Lee, Güllü Gorgün, Rifca Le Dieu, William Blum, John C. Byrd, John G. Gribben
Title and authors | Publication | Year |
---|---|---|
Tumor cells escape immunosurveillance by hampering LFA-1
Upadhyay S, Murugu L, Svensson L |
Frontiers in Immunology | 2025 |
Activation-induced thrombospondin-4 works with thrombospondin-1 to build cytotoxic supramolecular attack particles
Cassioli C, Capitani N, Staton CC, Schirra C, Finetti F, Onnis A, Alawar N, Tu SM, Lopresti L, Tatangelo V, Tangredi C, Valvo S, Chang HF, Miccoli A, Compeer EB, Nicholls J, Blazar BR, Marotta G, Wood MJ, Trentin L, Patrussi L, Dustin ML, Becherer U, Baldari CT |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
Normal Residual Lymphoid Cell Populations in Blood as Surrogate Biomarker of the Leukemia Cell Kinetics in CLL BinetA/Rai 0
Solano F, Criado I, Moreno N, Gomez-Gonzalez C, Lerma-Verdejo A, Teodosio C, Martinez-Moya MD, Luts I, Contreras T, Oliva-Ariza G, Fuentes Herrero B, Serrano-Lozano JM, Almeida J, Orfao A |
Cancers | 2025 |
Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review
Miklos DB, Riedell PA, Bokun A, Chavez JC, Schuster SJ |
Targeted Oncology | 2025 |
Cholesterol homeostasis and lipid raft dynamics at the basis of tumor-induced immune dysfunction in chronic lymphocytic leukemia
Jacobs CF, Peters FS, Camerini E, Cretenet G, Rietveld J, Schomakers BV, van Weeghel M, Hahn N, Verberk SG, Van den Bossche J, Langeveld M, Kleijwegt F, Eldering E, Zelcer N, Kater AP, Simon-Molas H |
Cellular and Molecular Immunology | 2025 |
The Elevation and Impact of Peripheral Bile Acids in Chronic Lymphocytic Leukemia
Smith AL, Ridout A, Skupa SA, Martinez-Rico R, Drengler EM, Mohamed E, D\u2019Angelo CR, El-Gamal D |
Biomedicines | 2025 |
Impact of mitochondrial metabolism on T-cell dysfunction in chronic lymphocytic leukemia
Gamal W, Mediavilla-Varela M, Kunta V, Sahakian E, Pinilla-Ibarz J |
Frontiers in Cell and Developmental Biology | 2025 |
Polyfunctional CD8(+)CD226(+)RUNX2(hi) effector T cells are diminished in advanced stages of chronic lymphocytic leukemia.
Rezaeifar M, Shahbaz S, Peters AC, Gibson SB, Elahi S |
Molecular oncology | 2025 |
Mitigating T-cell mitochondrial dysfunction in CLL to augment CAR T-cell therapy: evaluation in an immunocompetent model
Gamal W, Goedhart NB, Simon-Molas H, Mediavilla-Varela M, Uriepero-Palma A, Peters FS, Maharaj K, Chavez JC, Powers J, Obermayer A, Shaw TI, Conejo-Garcia JR, Rodriguez PC, Sahakian E, Pinilla-Ibarz J, Kater AP |
Blood Advances | 2025 |
A question of TiME: how microenvironmental interactions shape response to immunotherapy in CLL and Richter Transformation
vom Stein AF, Nguyen PH, ten Hacken E |
Frontiers in Immunology | 2025 |
BET inhibition reforms the immune microenvironment and alleviates T-cell dysfunction in chronic lymphocytic leukemia
Audrey Smith, Sydney Skupa, Alexandria Eiken, Elizabeth Schmitz, Nolan Williams, Dalia Moore, Christopher D'Angelo, Avyakta Kallam, Matthew Lunning, R Bociek, Julie Vose, Eslam Mohamed, Anna Mahr, Paul Denton, Ben Powell, Gideon Bollag, Dalia El-Gamal |
JCI Insight | 2024 |
Maintenance therapy for chronic lymphocytic leukaemia
Lee CH, Wu YY, Huang TC, Lin C, Zou YF, Cheng JC, Chen PH, Jhou HJ, Ho CL |
The Cochrane Database of Systematic Reviews | 2024 |
Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing.
Zhou Y, Wang D, Zhou L, Zhou N, Wang Z, Chen J, Pang R, Fu H, Huang Q, Dong F, Cheng H, Zhang H, Tang K, Ma J, Lv J, Cheng T, Fiskesund R, Zhang X, Huang B |
Nature Communications | 2024 |
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G, Tatangelo V, Lopresti L, Ulivieri C, Capitani N, Tangredi C, Finetti F, Marotta G, Frezzato F, Visentin A, Ciofini S, Gozzetti A, Bocchia M, Calzada-Fraile D, Martin Cofreces NB, Trentin L, Patrussi L, Baldari CT |
Cell Death and Disease | 2024 |
Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia.
Amatya C, Weissler KA, Fellowes V, Lam N, Cutmore LC, Natrakul DA, Highfill SL, Kochenderfer JN |
2024 | |
p66Shc deficiency in CLL cells enhances PD-L1 expression and suppresses immune synapse formation.
Lopresti L, Capitani N, Tatangelo V, Tangredi C, Boncompagni G, Frezzato F, Visentin A, Marotta G, Ciofini S, Gozzetti A, Bocchia M, Trentin L, Baldari CT, Patrussi L |
Frontiers in Cell and Developmental Biology | 2024 |
Advancing CAR T-cell therapy for chronic lymphocytic leukemia: exploring resistance mechanisms and the innovative strategies to overcome them
Borogovac A, Siddiqi T |
2024 | |
Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia
Nunes J, Tafesse R, Mao C, Purcell M, Mo X, Zhang L, Long M, Cyr MG, Rader C, Muthusamy N |
Nature Communications | 2024 |
Optimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia
Gamal W, Mediavilla-Varela M, Uriepero-Palma A, Pinilla-Ibarz J, Sahakian E |
International journal of molecular sciences | 2024 |
Vaccinations in Patient with Chronic Lymphocytic Leukemia
Francis ER, Vu J, Perez CO, Sun C |
Seminars in Hematology | 2024 |
Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.
Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, Röthemeier C, Neuber B, Hückelhoven-Krauss A, Brüggemann M, Bernhard H, Kobbe G, Lindemann A, Rummel M, Michels B, Korell F, Ho AD, Müller-Tidow C, Schmitt M |
Leukemia | 2024 |
T-cell dysfunction in CLL is mediated through expression of Siglec-10 ligands CD24 and CD52 on CLL cells
van Bruggen JA, Peters FS, Mes M, Rietveld JM, Cerretani E, Cretenet G, van Kampen R, Jongejan A, Moerland PD, Melenhorst JJ, van der Windt GJ, Eldering E, Kater AP |
Blood Advances | 2024 |
Pomalidomide in patients with multiple myeloma: potential impact on the reconstitution of a functional T-cell immunity.
Shen J, Senes F, Wen X, Monti P, Lin S, Pinna C, Murtas A, Podda L, Muntone G, Tidore G, Arru C, Sanna L, Contini S, Virdis P, Sechi LA, Fozza C |
Immunologic research | 2024 |
Assaying and classifying T cell function by cell morphology
Wang X, Fernandes SM, Brown JR, Kam LC |
BioMedInformatics | 2024 |
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
Yan Y, Tu Y, Cheng Q, Zhang J, Wang E, Deng Z, Yu Y, Wang L, Liu R, Chu L, Kang L, Liu J, Li X |
Journal of Translational Medicine | 2024 |
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
Heitmann JS, Jung S, Wacker M, Maringer Y, Nelde A, Bauer J, Denk M, Hoenisch-Gravel N, Richter M, Oezbek MT, Dubbelaar ML, Bilich T, Pumptow M, Martus P, Illerhaus G, Denzlinger C, Steinbach F, Aulitzky WE, Müller MR, Dörfel D, Rammensee H, Salih HR, Walz JS |
Frontiers in Immunology | 2024 |
Relapsed/refractory CLL: the role of allo-SCT, CAR-T, and T-cell engagers
Kater AP, Siddiqi T |
Hematology: the American Society of Hematology Education Program | 2024 |
Chronic lymphocytic leukemia presence impairs antigen-specific CD8+ T-cell responses through epigenetic reprogramming towards short-lived effectors
Martens AW, Kavazović I, Krapić M, Pack SM, Arens R, Jongejan A, Moerland PD, Eldering E, van der Windt GJ, Wensveen FM, Peters FS, Kater AP |
Leukemia | 2023 |
Emerging Therapies in CLL in the Era of Precision Medicine.
Iyer P, Wang L |
Cancers | 2023 |
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov AV |
Leukemia | 2023 |
Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia
Oder B, Chatzidimitriou A, Langerak AW, Rosenquist R, Österholm C |
Frontiers in Oncology | 2023 |
Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities
Brunell AE, Lahesmaa R, Autio A, Thotakura AK |
Frontiers in immunology | 2023 |
Pericyte-Glioblastoma Cell Interaction: A Key Target to Prevent Glioblastoma Progression.
Pombero A, Garcia-Lopez R, Martínez S |
Cells | 2023 |
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M |
Blood Advances | 2023 |
Severe Fatal Mucormycosis in a Patient with Chronic Lymphocytic Leukaemia Treated with Zanubrutinib: A Case Report and Review of the Literature
Maggioni G, Fedrigo M, Visentin A, Carturan E, Ruocco V, Trentin L, Alaibac M, Angelini A |
Current Oncology | 2023 |
T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
Lam V, Roleder C, Liu T, Bruss N, Best S, Wang X, Phillips T, Shouse G, Berger AJ, Alinari L, Wang L, Siddiqi T, Pennock ND, Danilov AV |
Molecular cancer therapeutics | 2023 |
Explainable machine learning for profiling the immunological synapse and functional characterization of therapeutic antibodies
Shetab Boushehri S, Essig K, Chlis NK, Herter S, Bacac M, Theis FJ, Glasmacher E, Marr C, Schmich F |
Nature Communications | 2023 |
CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep?
Vitale C, Griggio V, Perutelli F, Coscia M |
HemaSphere | 2023 |
Chronic Lymphocytic Leukemia: Disease Biology
Koehrer S, Burger JA |
Acta haematologica | 2023 |
EBAG9 controls CD8+ T cell memory formation responding to tumor challenge in mice
Armin Rehm, Anthea Wirges, Dana Hoser, Cornelius Fischer, Stefanie Herda, Kerstin Gerlach, Sascha Sauer, Gerald Willimsky, Uta Höpken |
JCI Insight | 2022 |
Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners
Byeongho Jung, Gerardo Ferrer, Pui Yan Chiu, Rukhsana Aslam, Anita Ng, Florencia Palacios, Michael Wysota, Martina Cardillo, Jonathan E. Kolitz, Steven L. Allen, Jacqueline C. Barrientos, Kanti R. Rai, Nicholas Chiorazzi, Barbara Sherry |
JCI Insight | 2022 |
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib
N Purroy, Y Tong, C Lemvigh, N Cieri, S Li, E Parry, W Zhang, L Rassenti, T Kipps, S Slager, N Kay, C Lesnick, T Shanafelt, P Ghia, L Scarfò, K Livak, P Kharchenko, D Neuberg, L Olsen, J Fan, S Gohil, C Wu |
Blood | 2022 |
PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
C Funk, S Wang, K Chen, A Waller, A Sharma, C Edgar, V Gupta, S Chandrakasan, J Zoine, A Fedanov, S Raikar, J Koff, C Flowers, S Coma, J Pachter, S Ravindranathan, H Spencer, M Shanmugam, E Waller |
Blood | 2022 |
Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia
F Forconi, S Lanham, G Chiodin |
Cancers | 2022 |
Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis
Boddicker NJ, Achenbach SJ, Parikh SA, Kleinstern G, Braggio E, Norman AD, Rabe KG, Vachon CM, Lesnick CE, Call TG, Olson JE, Cerhan JR, Kay NE, Hanson CA, Shanafelt TD, Slager SL |
Leukemia | 2022 |
Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis
Yu TY, Jhou HJ, Chen PH, Lee CH |
Current Oncology | 2022 |
Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection
Romano A, Cerchione C, Conticello C, Filetti S, Bulla A, Chiarenza A, Del Fabro V, Leotta S, Markovic U, Motta G, Parisi M, Stagno F, Palumbo GA, Di Raimondo F |
Cancers | 2022 |
CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings
Todorovic Z, Todorovic D, Markovic V, Ladjevac N, Zdravkovic N, Djurdjevic P, Arsenijevic N, Milovanovic M, Arsenijevic A, Milovanovic J |
Current Oncology | 2022 |
BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion.
Liu L, Cheng X, Yang H, Lian S, Jiang Y, Liang J, Chen X, Mo S, Shi Y, Zhao S, Li J, Jiang R, Yang DH, Wu Y |
Molecular Cancer | 2022 |
Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
van Bruggen JA, van der Windt GJ, Hoogendoorn M, Dubois J, Kater AP, Peters FS |
Blood Advances | 2022 |
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J |
Frontiers in immunology | 2022 |
CLL-Derived Extracellular Vesicles Impair T-Cell Activation and Foster T-Cell Exhaustion via Multiple Immunological Checkpoints
Böttcher M, Böttcher-Loschinski R, Kahlfuss S, Aigner M, Gießl A, Mackensen A, Schlötzer-Schrehardt U, Tüting T, Bruns H, Mougiakakos D |
Cells | 2022 |
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia
Liu Y, Song Y, Yin Q |
Frontiers in immunology | 2022 |
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms.
Guo H, Yang J, Wang H, Liu X, Liu Y, Zhou K |
Frontiers in immunology | 2022 |
CAR-T cell combination therapy: the next revolution in cancer treatment.
Al-Haideri M, Tondok SB, Safa SH, Maleki AH, Rostami S, Jalil AT, Al-Gazally ME, Alsaikhan F, Rizaev JA, Mohammad TAM, Tahmasebi S |
Cancer Cell International | 2022 |
Learning from TCR Signaling and Immunological Synapse Assembly to Build New Chimeric Antigen Receptors (CARs)
Cassioli C, Patrussi L, Valitutti S, Baldari CT |
International journal of molecular sciences | 2022 |
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C |
Journal for ImmunoTherapy of Cancer | 2022 |
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.
Yano M, Byrd JC, Muthusamy N |
Cancers | 2022 |
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia
Tettamanti S, Rotiroti MC, Attianese GM, Arcangeli S, Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Rodriguez TV, Barbaglio F, Scarfò L, Ponzoni M, Wierda W, Gandhi V, Keating MJ, Biondi A, Caligaris-Cappio F, Biagi E, Ghia P, Bertilaccio MT |
Leukemia & Lymphoma | 2022 |
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
Komissarov AA, Kislova M, Molodtsov IA, Petrenko AA, Dmitrieva E, Okuneva M, Peshkova IO, Shakirova NT, Potashnikova DM, Tvorogova AV, Ptushkin VV, Efimov GA, Nikitin EA, Vasilieva E |
International journal of molecular sciences | 2022 |
Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL
Collins MA, Jung IY, Zhao Z, Apodaca K, Kong W, Lundh S, Fraietta JA, Kater AP, Sun C, Wiestner A, Melenhorst JJ |
2022 | |
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O\u2019Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W |
Blood Advances | 2022 |
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Gamal W, Sahakian E, Pinilla-Ibarz J |
Blood Advances | 2022 |
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
N Ioannou, PR Hagner, M Stokes, AK Gandhi, B Apollonio, M Fanous, D Papazoglou, LA Sutton, R Rosenquist, RM Amini, H Chiu, A Lopez-Girona, P Janardhanan, FT Awan, J Jones, NE Kay, TD Shanafelt, MS Tallman, K Stamatopoulos, PE Patten, A Vardi, AG Ramsay |
Blood | 2021 |
Enhanced Expression of miR-181b in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response
MD Marco, S Veschi, P Lanuti, A Ramassone, S Pacillo, S Pagotto, F Pepe, JN George-William, C Curcio, M Marchisio, S Miscia, I Innocenti, F Autore, B Vannata, PD Gregorio, MD Gioacchino, S Valentinuzzi, M Iezzi, R Mariani-Costantini, LM Larocca, L Laurenti, A Veronese, R Visone |
Cancers | 2021 |
Multi-Factor Clustering Incorporating Cell Motility Predicts T Cell Expansion Potential
JH Lee, S Shao, M Kim, SM Fernandes, JR Brown, LC Kam |
Frontiers in Cell and Developmental Biology | 2021 |
T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies
V Janelle, JS Delisle |
Cancers | 2021 |
Biomechanics of T Cell Dysfunctions in Chronic Diseases
SD Gunasinghe, NG Peres, J Goyette, K Gaus |
Frontiers in immunology | 2021 |
T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
E Vlachonikola, K Stamatopoulos, A Chatzidimitriou |
Cancers | 2021 |
CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism
M Grioni, A Brevi, E Cattaneo, A Rovida, J Bordini, MT Bertilaccio, M Ponzoni, G Casorati, P Dellabona, P Ghia, M Bellone, A Calcinotto |
Blood Advances | 2021 |
Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target
C Cuesta-Mateos, JR Brown, F Terrón, C Muñoz-Calleja |
Frontiers in immunology | 2021 |
Chronic lymphocytic leukemia–like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia
G Blanco, A Puiggros, B Sherry, L Nonell, X Calvo, E Puigdecanet, PY Chiu, Y Kieso, G Ferrer, F Palacios, M Arnal, M Rodríguez-Rivera, E Gimeno, E Abella, KR Rai, P Abrisqueta, F Bosch, A Calon, A Ferrer, N Chiorazzi, B Espinet |
Experimental Hematology | 2021 |
CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia
G DArena, C Vitale, M Coscia, D Lamorte, G Pietrantuono, F Perutelli, F DAuria, T Statuto, L Valvano, A Tomasso, V Griggio, R Jones, G Mansueto, O Villani, S DAgostino, V Viglioglia, VD Feo, F Calapai, C Mannucci, A Sgambato, DG Efremov, L Laurenti |
Cancers | 2021 |
Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment
N Capitani, L Patrussi, CT Baldari |
International journal of molecular sciences | 2021 |
T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword
E Vlachonikola, K Stamatopoulos, A Chatzidimitriou |
Frontiers in immunology | 2021 |
Current State of CAR T-Cell Therapy in Chronic Lymphocytic Leukemia
V Mancikova, M Smida |
International journal of molecular sciences | 2021 |
Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively
C Moreno, C Muñoz, MJ Terol, JÁ Hernández-Rivas, M Villanueva |
Journal of Experimental & Clinical Cancer Research | 2021 |
Immunomodulatory Drugs for the Treatment of B Cell Malignancies
N Ioannou, K Jain, AG Ramsay |
International journal of molecular sciences | 2021 |
Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
A Allegra, A Tonacci, C Musolino, G Pioggia, S Gangemi |
Frontiers in immunology | 2021 |
BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL
M Mhibik, EM Gaglione, D Eik, EK Kendall, A Blackburn, K Keyvanfar, MJ Baptista, IE Ahn, C Sun, J Qi, C Rader, A Wiestner |
Blood | 2021 |
Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
C Sun, A Wiestner |
Hematology/Oncology Clinics of North America | 2021 |
Promising Immunotherapeutic Modalities for B-Cell Lymphoproliferative Disorders
J Mihályová, K Hradská, T Jelínek, B Motais, P Celichowski, R Hájek |
International journal of molecular sciences | 2021 |
Immunological and genetic kinetics from diagnosis to clinical progression in chronic lymphocytic leukemia
I Jiménez, B Tazón-Vega, P Abrisqueta, JC Nieto, S Bobillo, C Palacio-García, J Carabia, R Valdés-Mas, M Munuera, L Puigdefàbregas, G Parra, A Esteve-Codina, C Franco-Jarava, G Iacoboni, MJ Terol, JA García-Marco, M Crespo, F Bosch |
Biomarker Research | 2021 |
The Key Role of NAD+ in Anti-Tumor Immune Response: An Update
F Morandi, AL Horenstein, F Malavasi |
Frontiers in immunology | 2021 |
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives
M Kwok, A Agathanggelou, N Davies, T Stankovic |
Cancers | 2021 |
Neddylation and anti-tumor immunity
X Wang, S Best, AV Danilov |
Oncotarget | 2021 |
Targeting the tumor microenvironment in chronic lymphocytic leukemia
R Svanberg, S Janum, PE Patten, AG Ramsay, CU Niemann |
Haematologica | 2021 |
Expanded antigen-experienced CD160 + CD8 + effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia
N Bozorgmehr, I Okoye, O Oyegbami, L Xu, A Fontaine, N Cox-Kennett, LM Larratt, M Hnatiuk, A Fagarasanu, J Brandwein, AC Peters, S Elahi |
Journal for ImmunoTherapy of Cancer | 2021 |
The Peptide Vaccine of the Future
A Nelde, HG Rammensee, JS Walz |
Molecular & cellular proteomics : MCP | 2021 |
Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia
JR Rivas, Y Liu, SS Alhakeem, JM Eckenrode, F Marti, JP Collard, Y Zhang, KA Shaaban, N Muthusamy, GC Hildebrandt, RA Fleischman, L Chen, JS Thorson, M Leggas, S Bondada |
Leukemia | 2021 |
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
M Jan, AS Sperling, BL Ebert |
Nature Reviews Clinical Oncology | 2021 |
Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphoma
C Ménard, D Rossille, J Dulong, TT Nguyen, I Papa, M Latour, N Bescher, I Bezier, M Chouteau, T Fest, R Houot, F Morschhauser, K Tarte |
Blood Advances | 2021 |
EOMES is essential for antitumor activity of CD8+ T cells in chronic lymphocytic leukemia
L Llaó-Cid, PM Roessner, V Chapaprieta, S Öztürk, T Roider, M Bordas, A Izcue, D Colomer, S Dietrich, S Stilgenbauer, B Hanna, JI Martín-Subero, M Seiffert |
Leukemia | 2021 |
The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)
JA Whitaker, SA Parikh, TD Shanafelt, NE Kay, RB Kennedy, DE Grill, KM Goergen, TG Call, SS Kendarian, W Ding, GA Poland |
Vaccine | 2021 |
Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective
M Kwok, CJ Wu |
Frontiers in Oncology | 2021 |
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis
Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Scott Schmid D, Kennedy RB, Weinberg A, Parikh SA |
American Journal of Hematology | 2021 |
Long-term Follow-up and Correlative Analysis of two Phase 2 Trials of Rituximab and Lenalidomide followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E |
Clinical cancer research | 2021 |
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG |
Blood | 2021 |
Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
M Giuliani, A Poggi |
Cells | 2020 |
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies
Y Kikushige |
Journal of Clinical and Experimental Hematopathology | 2020 |
Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL:
T Hofland, I de Weerdt, S Endstra, A Jongejan, L Platenkamp, EB Remmerswaal, PD Moerland, IJ ten Berge, MD Levin, AP Kater, SH Tonino |
2020 | |
Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells
S Best, , T Liu, N Bruss, A Kittai, OV Danilova, S Murray, A Berger, ND Pennock, EF Lind, AV Danilov |
Leukemia | 2020 |
T-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
PM Roessner, M Seiffert |
Leukemia | 2020 |
CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
AW Martens, SR Janssen, IA Derks, HC Adams, L Izhak, R van Kampen, SH Tonino, E Eldering, GJ van der Windt, AP Kater |
Journal for ImmunoTherapy of Cancer | 2020 |
Human CXCR5 + PD‐1 + CD8 T cells in healthy individuals and patients with hematologic malignancies
T Hofland, AW Martens, JA Bruggen, R Boer, S Schetters, EB Remmerswaal, FJ Bemelman, MD Levin, AD Bins, E Eldering, AP Kater, SH Tonino |
European Journal of Immunology | 2020 |
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia
V Griggio, F Perutelli, C Salvetti, E Boccellato, M Boccadoro, C Vitale, M Coscia |
Frontiers in immunology | 2020 |
Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis
S Yi, Y Zhang, W Xiong, W Chen, Z Hou, Y Yang, Y Yan, Y Wei, R Cui, H Wang, Z Yu, H Li, Z Li, W Liu, R Lv, T Wang, K Ru, D Zou, M Shu, L Qiu, D Yu |
IBMS BoneKEy | 2020 |
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse
S Cadot, C Valle, M Tosolini, F Pont, L Largeaud, C Laurent, JJ Fournie, L Ysebaert, A Quillet-Mary |
Biomarker Research | 2020 |
Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome
H Augé, AB Notarantonio, R Morizot, A Quinquenel, LM Fornecker, S Hergalant, P Feugier, J Broséus |
Frontiers in immunology | 2020 |
Modeling the Leukemia Microenviroment In Vitro
C Scielzo, P Ghia |
Frontiers in Oncology | 2020 |
Mechanisms of resistance to CAR T cell therapies
N Singh, E Orlando, J Xu, J Xu, Z Binder, MK Collins, DM ORourke, JJ Melenhorst |
Seminars in Cancer Biology | 2020 |
Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
Z Wang, G Zhou, N Risu, J Fu, Y Zou, J Tang, L Li, H Liu, Q Liu, X Zhu |
Cell Transplantation | 2020 |
PD-1 Inhibition in Malignant Melanoma and Lack of Clinical Response in Chronic Lymphocytic Leukemia in the Same Patients: A Case Series
I Landego, D Hewitt, I Hibbert, D Dhaliwal, W Pieterse, D Grenier, R Wong, J Johnston, V Banerji |
Current Oncology | 2020 |
Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses
A Manna, T Kellett, S Aulakh, LJ Lewis-Tuffin, N Dutta, K Knutson, E Chini, J Pinilla-Ibarz, N Lamanna, R Manochakian, F Malavasi, T Sher, AA Chanan-Khan, S Ailawadhi, A Paulus |
Blood Advances | 2020 |
Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)
TD Shanafelt, NE Kay, SA Parikh, SJ Achenbach, CE Lesnick, CA Hanson, G Kleinstern, JE Olson, AD Norman, KG Rabe, SM Schwager, TG Call, SL Slager |
Leukemia | 2020 |
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia
P Banerjee, R Zhang, C Ivan, G Galletti, K Clise-Dwyer, F Barbaglio, L Scarfò, M Aracil, C Klein, W Wierda, W Plunkett, F Caligaris-Cappio, V Gandhi, MJ Keating, MT Bertilaccio |
Cancer immunology research | 2019 |
SLAMF6 in health and disease: Implications for therapeutic targeting
B Yigit, N Wang, R Herzog, C Terhorst |
Clinical Immunology | 2019 |
Actin Cytoskeleton Straddling the Immunological Synapse between Cytotoxic Lymphocytes and Cancer Cells
H Wurzer, C Hoffmann, AA Absi, C Thomas |
Cells | 2019 |
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
Mulder, Wahlin, Österborg, Palma |
Cancers | 2019 |
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
I de Weerdt, T Hofland, R de Boer, JA Dobber, J Dubois, D van Nieuwenhuize, M Mobasher, F de Boer, M Hoogendoorn, GA Velders, M van der Klift, EB Remmerswaal, FJ Bemelman, CU Niemann, S Kersting, MD Levin, E Eldering, SH Tonino, AP Kater |
Blood Advances | 2019 |
Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia
T Hofland, E Eldering, AP Kater, SH Tonino |
International journal of molecular sciences | 2019 |
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
JA van Bruggen, AW Martens, JA Fraietta, T Hofland, SH Tonino, E Eldering, MD Levin, PJ Siska, S Endstra, JC Rathmell, CH June, DL Porter, JJ Melenhorst, AP Kater, GJ van der Windt |
Blood | 2019 |
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
M Mhibik, A Wiestner, C Sun |
International journal of molecular sciences | 2019 |
Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling:
T Hofland, S Endstra, CK Gomes, R de Boer, I de Weerdt, V Bobkov, JA Riedl, R Heukers, MJ Smit, E Eldering, MD Levin, AP Kater, SH Tonino |
2019 | |
Dissecting CLL through high-dimensional single-cell technologies
SH Gohil, CJ Wu |
Blood | 2019 |
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
P Strati, K Takahashi, CB Peterson, MJ Keating, PA Thompson, NG Daver, N Jain, JA Burger, Z Estrov, SM O'Brien, HM Kantarjian, WG Wierda, PA Futreal, A Ferrajoli |
Blood Advances | 2019 |
Multiparametric analysis of CD8 + T cell compartment phenotype in chronic lymphocytic leukemia reveals a signature associated with progression toward therapy
P Gonnord, M Costa, A Abreu, M Peres, L Ysebaert, S Gadat, S Valitutti |
OncoImmunology | 2019 |
Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma
H Chiu, P Trisal, C Bjorklund, S Carrancio, EG Toraño, C Guarinos, D Papazoglou, PR Hagner, A BeldiFerchiou, K Tarte, MH DelfauLarue, F Morschhauser, AG Ramsay, AK Gandhi |
British Journal of Haematology | 2019 |
Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma
AM Lesokhin, S Bal, AZ Badros |
Cancer immunology research | 2019 |
B-cell–specific IRF4 deletion accelerates chronic lymphocytic leukemia development by enhanced tumor immune evasion
D Asslaber, Y Qi, N Maeding, M Steiner, U Denk, JP Höpner, TN Hartmann, N Zaborsky, R Greil, A Egle |
Blood | 2019 |
Battle of Thermopylae: 300 Spartans (natural killer cells plus obinutuzumab) versus the immortal warriors (chronic lymphocytic leukemia cells) of Xerxes’ army
R García-Muñoz, MJ Nájera, J Feliu, J Antón-Remírez, E Ramalle-Gómara, R Marín-Gorricho, R Peralta, E Gutiérrez-Gamarra, J Nuñez-Rodriguez, R Zafra-Morales, L Aguinaga, MJ Nebot-Villacampa, PM Hernandez-Pérez, G Farfán-Quiroga, C Panizo, E Domínguez-Garrido |
Future Science OA | 2019 |
IMiDs New and Old
S Yamshon, J Ruan |
Current Hematologic Malignancy Reports | 2019 |
Maintenance therapy for chronic lymphocytic leukaemia
Lee C, Wu Y, Huang T, Lin C, Zou Y, Cheng J, Ho C |
The Cochrane Database of Systematic Reviews | 2019 |
PI3K p110δ inactivation antagonizes Chronic Lymphocytic Leukemia and reverses T-cell immune suppression
Shuai Dong, Bonnie K. Harrington, Eileen Hu, Joseph T. Greene, Amy Lehman, Minh H Tran, Ronni Wasmuth, Meixiao Long, Natarajan Muthusamy, Jennifer R. Brown, Amy J Johnson, John C. Byrd |
Journal of Clinical Investigation | 2018 |
The CXCR4–STAT3–IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide
H Shaim, Z Estrov, D Harris, MH Sanabria, Z Liu, P Ruvolo, PA Thompson, A Ferrajoli, M Daher, J Burger, M Muftuoglu, N Imahashi, L Li, E Liu, AS Alsuliman, R Basar, LN Kerbauy, C Sobieski, E Gokdemir, K Kondo, W Wierda, M Keating, EJ Shpall, K Rezvani |
Frontiers in immunology | 2018 |
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
P Kokhaei, M Hojjat-Farsangi, F Mozaffari, A Moshfegh, F Pak, A Rashidy-Pour, M Palma, L Hansson, A Österborg, H Mellstedt, SB Gibson |
PloS one | 2018 |
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era
HR Robinson, J Qi, EM Cook, C Nichols, EL Dadashian, C Underbayev, SE Herman, NS Saba, K Keyvanfar, C Sun, IE Ahn, S Baskar, C Rader, A Wiestner |
Blood | 2018 |
Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity
SS Alhakeem, MK McKenna, KZ Oben, SK Noothi, JR Rivas, GC Hildebrandt, RA Fleischman, VM Rangnekar, N Muthusamy, S Bondada |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
How and when I do allogeneic transplant in CLL
JG Gribben |
Blood | 2018 |
Activation of Th1 Immunity within the Tumor Microenvironment Is Associated with Clinical Response to Lenalidomide in Chronic Lymphocytic Leukemia
G Aue, C Sun, D Liu, JH Park, S Pittaluga, X Tian, E Lee, S Soto, J Valdez, I Maric, M Stetler-Stevenson, C Yuan, Y Nakamura, P Muranski, A Wiestner |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
Signals Controlling Lytic Granule Polarization at the Cytotoxic Immune Synapse
A Kabanova, V Zurli, CT Baldari |
Frontiers in immunology | 2018 |
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia
C Pleyer, A Wiestner, C Sun |
Leukemia & Lymphoma | 2018 |
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study
A Egle, M Steurer, T Melchardt, L Weiss, FJ Gassner, N Zaborsky, R Geisberger, K Catakovic, TN Hartmann, L Pleyer, D Voskova, J Thaler, A Lang, M Girschikofsky, A Petzer, R Greil |
Annals of Hematology | 2018 |
Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues
BS Hanna, PM Roessner, H Yazdanparast, D Colomer, E Campo, S Kugler, D Yosifov, S Stilgenbauer, M Schmidt, R Gabriel, P Lichter, M Seiffert |
Leukemia | 2018 |
Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia
C Vitale, A Ferrajoli |
Haematologica | 2018 |
Enhanced Activation and Expansion of T Cells Using Mechanically Soft Elastomer Fibers
AP Dang, SD Leo, DR Bogdanowicz, DJ Yuan, SM Fernandes, JR Brown, HH Lu, LC Kam |
Advanced Biosystems | 2018 |
Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma
B Hu, R Jacobs, N Ghosh |
Current Hematologic Malignancy Reports | 2018 |
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
BS Hanna, PM Roessner, A Scheffold, BM Jebaraj, Y Demerdash, S Öztürk, P Lichter, S Stilgenbauer, M Seiffert |
Leukemia | 2018 |
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation
S Ringelstein-Harlev, I Avivi, M Fanadka, NA Horowitz, T Katz |
Cancer Immunology, Immunotherapy | 2018 |
TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia
K Catakovic, FJ Gassner, C Ratswohl, N Zaborsky, S Rebhandl, M Schubert, M Steiner, JC Gutjahr, L Pleyer, A Egle, TN Hartmann, R Greil, R Geisberger |
OncoImmunology | 2017 |
Precancer Atlas to Drive Precision Prevention Trials
A Spira, MB Yurgelun, L Alexandrov, A Rao, R Bejar, K Polyak, M Giannakis, A Shilatifard, OJ Finn, M Dhodapkar, NE Kay, E Braggio, E Vilar, SA Mazzilli, TR Rebbeck, JE Garber, VE Velculescu, ML Disis, DC Wallace, SM Lippman |
Cancer research | 2017 |
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
ZY Xu-Monette, M Zhang, J Li, KH Young |
Frontiers in immunology | 2017 |
Chronic lymphocytic leukaemia
TJ Kipps, FK Stevenson, CJ Wu, CM Croce, G Packham, WG Wierda, S O'Brien, J Gribben, K Rai |
Nature Reviews Disease Primers | 2017 |
Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome
KJ Till, JC Allen, F Talab, K Lin, D Allsup, L Cawkwell, A Bentley, I Ringshausen, AD Duckworth, AR Pettitt, N Kalakonda, JR Slupsky |
Scientific Reports | 2017 |
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia
Q Yin, M Sivina, H Robins, E Yusko, M Vignali, S OBrien, MJ Keating, A Ferrajoli, Z Estrov, N Jain, WG Wierda, JA Burger |
Journal of immunology (Baltimore, Md. : 1950) | 2017 |
Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia
N Purroy, CJ Wu |
Cold Spring Harbor Perspectives in Medicine | 2017 |
Using Murine Models to Investigate Tumor–Lymphoid Interactions: Spotlight on Chronic Lymphocytic Leukemia and Angioimmunoblastic T-Cell Lymphoma
TA Herek, CE Cutucache |
Frontiers in Oncology | 2017 |
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia
K Maharaj, E Sahakian, J Pinilla-Ibarz |
Blood Advances | 2017 |
Role of LFA-1 and ICAM-1 in Cancer
M Reina, E Espel |
Cancers | 2017 |
Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
PA Thompson, JA Burger |
Expert Opinion on Investigational Drugs | 2017 |
Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
AD Fesnak, PJ Hanley, BL Levine |
Current Hematologic Malignancy Reports | 2017 |
A novel AHI-1–BCR-ABL–DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy
X Liu, K Rothe, R Yen, C Fruhstorfer, T Maetzig, M Chen, DL Forrest, RK Humphries, X Jiang |
Leukemia | 2017 |
Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia
M Villa-Álvarez, S Lorenzo-Herrero, AP Gonzalez-Rodriguez, A López-Soto, AR Payer, E Gonzalez-Garcia, L Huergo-Zapico, S Gonzalez |
OncoImmunology | 2017 |
Nurse-like cells promote CLL survival through LFA-3/CD2 interactions
F Boissard, M Tosolini, L Ligat, A Quillet-Mary, F Lopez, JJ Fournié, L Ysebaert, M Poupot |
Oncotarget | 2017 |
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017
T Jelinek, J Mihalyova, M Kascak, J Duras, R Hajek |
Immunology | 2017 |
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
W Ding, BR LaPlant, TG Call, SA Parikh, JF Leis, R He, TD Shanafelt, S Sinha, J Le-Rademacher, AL Feldman, TM Habermann, TE Witzig, GA Wiseman, Y Lin, E Asmus, GS Nowakowski, MJ Conte, DA Bowen, CN Aitken, DL van Dyke, PT Greipp, X Liu, X Wu, H Zhang, CR Secreto, S Tian, E Braggio, LE Wellik, I Micallef, DS Viswanatha, H Yan, AA Chanan-Khan, NE Kay, H Dong, SM Ansell |
Blood | 2017 |
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway
K Kondo, H Shaim, PA Thompson, JA Burger, M Keating, Z Estrov, D Harris, E Kim, A Ferrajoli, M Daher, R Basar, M Muftuoglu, N Imahashi, A Alsuliman, C Sobieski, E Gokdemir, W Wierda, N Jain, E Liu, EJ Shpall, K Rezvani |
Leukemia | 2017 |
Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
MH van Attekum, E Eldering, AP Kater |
Haematologica | 2017 |
αII-spectrin in T cells is involved in the regulation of cell-cell contact leading to immunological synapse formation?
JM Meissner, AF Sikorski, T Nawara, J Grzesiak, K Marycz, DM Bogusławska, I Michalczyk, MC Lecomte, B Machnicka, AA Ansari |
PloS one | 2017 |
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy
S Schliffke, M Sivina, E Kim, L Wenserski, B Thiele, N Akyüz, C Falker-Gieske, D Statovci, A Oberle, T Thenhausen, A Krohn-Grimberghe, C Bokemeyer, N Jain, Z Estrov, A Ferrajoli, W Wierda, M Keating, JA Burger, M Binder |
OncoImmunology | 2017 |
HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
A Nelde, DJ Kowalewski, L Backert, H Schuster, JO Werner, R Klein, O Kohlbacher, L Kanz, HR Salih, HG Rammensee, S Stevanović, JS Walz |
OncoImmunology | 2017 |
Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a non-classical Th1-dependent, Bcl-6-deficient process
Piers Patten, Gerardo Ferrer, Shih-Shih Chen, Rita Simone, Sonia Marsilio, Xiao-Jie Yan, Zachary Gitto, Chaohui Yuan, Jonathan Kolitz, Jacqueline Barrientos, Steven Allen, Kanti Rai, Thomas MacCarthy, Charles Chu, Nicholas Chiorazzi |
JCI Insight | 2016 |
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells
JA Fraietta, RD Schwab, MV Maus |
Seminars in Oncology | 2016 |
Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia
A Mohr, Y Renaudineau, C Bagacean, JO Pers, C Jamin, A Bordron |
OncoImmunology | 2016 |
Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements
A Vardi, E Vlachonikola, M Karypidou, E Stalika, V Bikos, K Gemenetzi, C Maramis, A Siorenta, A Anagnostopoulos, S Pospisilova, N Maglaveras, I Chouvarda, K Stamatopoulos, A Hadzidimitriou |
Leukemia | 2016 |
Phenotypic alteration of CD8+ T cells in chronic lymphocytic leukemia is associated with epigenetic reprogramming
J Wu, X Xu, EJ Lee, AY Shull, L Pei, F Awan, X Wang, JH Choi, L Deng, HB Xin, W Zhong, J Liang, Y Miao, Y Wu, L Fan, J Li, W Xu, H Shi |
Oncotarget | 2016 |
TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia
A Bresin, L D'Abundo, MG Narducci, MT Fiorenza, CM Croce, M Negrini, G Russo |
Cell Death and Disease | 2016 |
Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART before the Horse
SS Kenderian, DL Porter, S Gill |
Biology of Blood and Marrow Transplantation | 2016 |
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
M Winqvist, F Mozaffari, M Palma, SE Sylvan, L Hansson, H Mellstedt, A Österborg, J Lundin |
Cancer Immunology, Immunotherapy | 2016 |
Ibrutinib as an antitumor immunomodulator in patients with refractory chronic lymphocytic leukemia
C Cubillos-Zapata, J Avendaño-Ortiz, R Córdoba, E Hernández-Jiménez, V Toledano, RP de Diego, E López-Collazo |
OncoImmunology | 2016 |
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
CE Ryan, B Sahaf, AC Logan, S OBrien, JC Byrd, P Hillmen, JR Brown, MJ Dyer, AR Mato, MJ Keating, S Jaglowski, F Clow, AR Rezvani, L Styles, SE Coutre, DB Miklos |
Blood | 2016 |
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
M Palma, G Gentilcore, K Heimersson, F Mozaffari, B Näsman-Glaser, E Young, R Rosenquist, L Hansson, A Österborg, H Mellstedt |
Haematologica | 2016 |
'Trained immunity: consequences for lymphoid malignancies
WB Stevens, MG Netea, AP Kater, WJ van der Velden |
Haematologica | 2016 |
Expression of the p66Shc protein adaptor is regulated by the activator of transcription STAT4 in normal and chronic lymphocytic leukemia B cells
F Cattaneo, L Patrussi, N Capitani, F Frezzato, MM DElios, L Trentin, G Semenzato, CT Baldari |
Oncotarget | 2016 |
CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells
N Zaborsky, FJ Gassner, D Asslaber, P Reinthaler, U Denk, S Flenady, JP Hofbauer, B Danner, S Rebhandl, A Harrer, R Geisberger, R Greil, A Egle |
Oncotarget | 2016 |
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics
C Vitale, L Falchi, E Hacken, H Gao, H Shaim, KV Roosbroeck, G Calin, S O'Brien, S Faderl, X Wang, WG Wierda, K Rezvani, JM Reuben, JA Burger, MJ Keating, A Ferrajoli |
Clinical cancer research | 2016 |
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia
M Qorraj, H Bruns, M Böttcher, L Weigand, D Saul, A Mackensen, R Jitschin, D Mougiakakos |
Leukemia | 2016 |
Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells
RL Browning, WH Byrd, N Gupta, J Jones, X Mo, E Hertlein, L Yu, N Muthusamy, JC Byrd |
Cancer immunology research | 2016 |
Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells
M Pizzi, M Boi, F Bertoni, G Inghirami |
Leukemia | 2016 |
Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation
MA Grygorowicz, IS Borycka, E Nowak, E Paszkiewicz-Kozik, G Rymkiewicz, K Błachnio, M Biernacka, M Bujko, J Walewski, S Markowicz |
Clinical and Experimental Medicine | 2016 |
B cells and macrophages pursue a common path toward the development and progression of chronic lymphocytic leukemia
G Galletti, F Caligaris-Cappio, MT Bertilaccio |
Leukemia | 2016 |
Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting
SH Bachow, N Lamanna |
Current Hematologic Malignancy Reports | 2016 |
Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
E Hacken, JA Burger |
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research | 2015 |
Haematological malignancies: at the forefront of immunotherapeutic innovation
P Bachireddy, UE Burkhardt, M Rajasagi, CJ Wu |
Nature Reviews Cancer | 2015 |
Targeted Therapy for Chronic Lymphocytic Leukemia: Current Status and Future Directions
JE Arnason, JR Brown |
Drugs | 2015 |
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors
Maël Heiblig, Mohamed Elhamri, Mauricette Michallet, Xavier Thomas |
World journal of stem cells | 2015 |
PD-L1 Checkpoint Blockade Prevents Immune Dysfunction and Leukemia Development in a Mouse Model of Chronic Lymphocytic Leukemia
F McClanahan, B Hanna, S Miller, AJ Clear, P Lichter, JG Gribben, M Seiffert |
Blood | 2015 |
Impaired T-Cell Function in B-Cell Lymphoma: A Direct Consequence of Events at the Immunological Synapse?
MN Roufaiel, JW Wells, RJ Steptoe |
Frontiers in immunology | 2015 |
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E -TCL1 CLL mouse model
F McClanahan, JC Riches, S Miller, WP Day, E Kotsiou, D Neuberg, CM Croce, M Capasso, JG Gribben |
Blood | 2015 |
Lymphoma: Immune Evasion Strategies
R Upadhyay, L Hammerich, P Peng, B Brown, M Merad, J Brody |
Cancers | 2015 |
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells
D Saulep-Easton, FB Vincent, PS Quah, A Wei, SB Ting, CM Croce, C Tam, F Mackay |
Leukemia | 2015 |
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib
R Maffei, S Fiorcari, S Martinelli, L Potenza, M Luppi, R Marasca |
Journal of Hematology & Oncology | 2015 |
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
A Kritharis, M Coyle, J Sharma, AM Evens |
Blood | 2015 |
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
AP Rapoport, EA Stadtmauer, GK Binder-Scholl, O Goloubeva, DT Vogl, SF Lacey, AZ Badros, A Garfall, B Weiss, J Finklestein, I Kulikovskaya, SK Sinha, S Kronsberg, M Gupta, S Bond, L Melchiori, JE Brewer, AD Bennett, AB Gerry, NJ Pumphrey, D Williams, HK Martin, L Ribeiro, T Holdich, S Yanovich, N Hardy, J Yared, N Kerr, S Philip, S Westphal, DL Siegel, BL Levine, BK Jakobsen, M Kalos, CH June |
Nature Medicine | 2015 |
Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date
K Crassini |
World journal of clinical cases | 2015 |
Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells
P Otáhal, D Průková, V Král, M Fabry, P Vočková, L Latečková, M Trněný, P Klener |
OncoImmunology | 2015 |
Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)
K Ishii, AJ Barrett |
Therapeutic Advances in Hematology | 2015 |
Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes
B Sherry, P Jain, PY Chiu, L Leung, SL Allen, JE Kolitz, KR Rai, J Barrientos, S Liang, R Hawtin, N Chiorazzi |
Immunologic Research | 2015 |
Initial treatment of CLL: integrating biology and functional status
N Jain, S O'Brien |
Blood | 2015 |
Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
FJ Gassner, N Zaborsky, K Catakovic, S Rebhandl, M Huemer, A Egle, TN Hartmann, R Greil, R Geisberger |
British Journal of Haematology | 2015 |
B cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T cell clonality in chronic lymphocytic leukemia
N Zaborsky, C Holler, R Geisberger, D Asslaber, FJ Gassner, V Egger, J Pinon-Hofbauer, T Kocher, TN Hartmann, R Greil, A Egle |
Haematologica | 2015 |
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo
BS Hanna, F McClanahan, H Yazdanparast, N Zaborsky, V Kalter, PM Rößner, A Benner, C Dürr, A Egle, JG Gribben, P Lichter, M Seiffert |
Leukemia | 2015 |
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
DL Porter, WT Hwang, NV Frey, SF Lacey, PA Shaw, AW Loren, A Bagg, KT Marcucci, A Shen, V Gonzalez, D Ambrose, SA Grupp, A Chew, Z Zheng, MC Milone, BL Levine, JJ Melenhorst, CH June |
Science Translational Medicine | 2015 |
Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses
S Kuramitsu, M Ohno, F Ohka, S Shiina, A Yamamichi, A Kato, K Tanahashi, K Motomura, G Kondo, M Kurimoto, T Senga, T Wakabayashi, A Natsume |
Cancer Gene Therapy | 2015 |
Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?
R García-Muñoz, L Llorente |
Immunology | 2014 |
The Immunological Synapse
ML Dustin |
Cancer immunology research | 2014 |
The CD37-targeted antibody–drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
KA Beckwith, FW Frissora, MR Stefanovski, WH Towns, C Cheney, X Mo, J Deckert, CM Croce, JM Flynn, LA Andritsos, JA Jones, KJ Maddocks, G Lozanski, JC Byrd, N Muthusamy |
Leukemia | 2014 |
Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21WAF1/Cip1-dependent mechanism independent of functional p53
JF Fecteau, LG Corral, EM Ghia, S Gaidarova, D Futalan, IS Bharati, B Cathers, M Schwaederle, B Cui, A Lopez-Girona, D Messmer, TJ Kipps |
Blood | 2014 |
Involvement of memory T-cells in the pathophysiology of chronic lymphocytic leukemia
RP Correia, FA Silva, NS Bacal, PV Campregher, N Hamerschlak, GP Amarante-Mendes |
Revista Brasileira de Hematologia e Hemoterapia | 2014 |
CD1d levels in peripheral blood of patients with acute myeloid leukemia and acute lymphoblastic leukemia
W Guo, A Dong, C Xing, X Lin, X Pan, Y Lin, B Zhu, M He, RX Yao |
Oncology Letters | 2014 |
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia
S Fiorcari, S Martinelli, J Bulgarelli, V Audrito, P Zucchini, E Colaci, L Potenza, F Narni, M Luppi, S Deaglio, R Marasca, R Maffei |
Haematologica | 2014 |
Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
A Acebes-Huerta, L Huergo-Zapico, AP Gonzalez-Rodriguez, A Fernandez-Guizan, AR Payer, A López-Soto, S Gonzalez |
BioMed Research International | 2014 |
Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia
FJ Gassner, N Zaborsky, D Neureiter, M Huemer, T Melchardt, A Egle, S Rebhandl, K Catakovic, TN Hartmann, R Greil, R Geisberger |
Haematologica | 2014 |
Lenalidomide, an antiproliferative CLL drug
M Seiffert |
Blood | 2014 |
How will B-cell-receptor-targeted therapies change future CLL therapy?
Jeffrey A Jones, John C Byrd |
Blood | 2014 |
Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
L Huergo-Zapico, A Acebes-Huerta, AP Gonzalez-Rodriguez, J Contesti, E Gonzalez-García, AR Payer, M Villa-Alvarez, A Fernández-Guizán, A López-Soto, S Gonzalez, SB Gibson |
PloS one | 2014 |
Transplantation in Chronic Lymphocytic Leukemia
F McClanahan, J Gribben |
Hematology/Oncology Clinics of North America | 2014 |
Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician
JC Byrd, JJ Jones, JA Woyach, AJ Johnson, JM Flynn |
Journal of Clinical Oncology | 2014 |
Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphocytic Leukemia Research Consortium
DF James, L Werner, JR Brown, WG Wierda, JC Barrientos, JE Castro, A Greaves, AJ Johnson, LZ Rassenti, KR Rai, D Neuberg, TJ Kipps |
Journal of Clinical Oncology | 2014 |
Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells
AP Rapoport, NA Aqui, EA Stadtmauer, DT Vogl, YY Xu, M Kalos, L Cai, HB Fang, BM Weiss, A Badros, S Yanovich, G Akpek, P Tsao, A Cross, D Mann, S Philip, N Kerr, A Brennan, Z Zheng, K Ruehle, T Milliron, SE Strome, AM Salazar, BL Levine, CH June |
Clinical cancer research | 2014 |
The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
Patton JT, Lustberg ME, Lozanski G, Garman SL, Towns WH, Drohan CM, Lehman A, Zhang X, Bolon B, Pan L, Kinghorn AD, Grever MR, Lucas DM, Baiocchi RA |
Oncotarget | 2014 |
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
Van Lint S, Wilgenhof S, Heirman C, Corthals J, Breckpot K, Bonehill A, Neyns B, Thielemans K |
Cancer Immunology, Immunotherapy | 2014 |
Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation
S Kiaii, AJ Clear, AG Ramsay, D Davies, A Sangaralingam, A Lee, M Calaminici, DS Neuberg, JG Gribben |
Journal of Clinical Oncology | 2013 |
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
JA Dubovsky, KA Beckwith, G Natarajan, JA Woyach, S Jaglowski, Y Zhong, JD Hessler, TM Liu, BY Chang, KM Larkin, MR Stefanovski, DL Chappell, FW Frissora, LL Smith, KA Smucker, JM Flynn, JA Jones, LA Andritsos, K Maddocks, AM Lehman, R Furman, J Sharman, A Mishra, MA Caligiuri, AR Satoskar, JJ Buggy, N Muthusamy, AJ Johnson, JC Byrd |
Blood | 2013 |
Targeting inflammatory pathways in chronic lymphocytic leukemia
U Rozovski, MJ Keating, Z Estrov |
Critical Reviews in Oncology/Hematology | 2013 |
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications
Y Herishanu, BZ Katz, A Lipsky, A Wiestner |
Hematology/Oncology Clinics of North America | 2013 |
The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia
G Brachtl, JP Hofbauer, R Greil, TN Hartmann |
Annals of Hematology | 2013 |
Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide
AG Ramsay, R Evans, S Kiaii, L Svensson, N Hogg, JG Gribben |
Blood | 2013 |
Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia
W Guo, C Xing, A Dong, X Lin, Y Lin, B Zhu, M He, R Yao |
Cancer biology & therapy | 2013 |
Lenalidomide and chronic lymphocytic leukemia
AP González-Rodríguez, AR Payer, A Acebes-Huerta, L Huergo-Zapico, M Villa-Alvarez, E Gonzalez-García, S Gonzalez |
BioMed Research International | 2013 |
The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia
D Brusa, S Serra, M Coscia, D Rossi, G D'Arena, L Laurenti, O Jaksic, G Fedele, G Inghirami, G Gaidano, F Malavasi, S Deaglio |
Haematologica | 2013 |
Current Topics in Membranes
S Curado, S Kumari, ML Dustin |
Current topics in membranes | 2013 |
Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
R Wong, C Pepper, P Brennan, D Nagorsen, S Man, C Fegan |
Haematologica | 2013 |
Trial Watch: Lenalidomide-based immunochemotherapy
M Semeraro, E Vacchelli, A Eggermont, J Galon, L Zitvogel, G Kroemer, L Galluzzi |
OncoImmunology | 2013 |
HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism
R Rizzo, V Audrito, P Vacca, D Rossi, D Brusa, M Stignani, D Bortolotti, G D'Arena, M Coscia, L Laurenti, F Forconi, G Gaidano, MC Mingari, L Moretta, F Malavasi, S Deaglio |
Haematologica | 2013 |
CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation
Y Nakaima, K Watanabe, T Koyama, O Miura, T Fukuda |
PloS one | 2013 |
Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
MA Kharfan-Dabaja, WG Wierda, LJ Cooper |
Leukemia | 2013 |
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
P Strati, MJ Keating, WG Wierda, XC Badoux, S Calin, JM Reuben, S O'Brien, SM Kornblau, HM Kantarjian, H Gao, A Ferrajoli |
Blood | 2013 |
T Cell Ig and Mucin Domain-Containing Protein 3 Is Recruited to the Immune Synapse, Disrupts Stable Synapse Formation, and Associates with Receptor Phosphatases
KL Clayton, MS Haaland, MB Douglas-Vail, S Mujib, GM Chew, LC Ndhlovu, MA Ostrowski |
Journal of immunology (Baltimore, Md. : 1950) | 2013 |
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4 CRBN
AK Gandhi, J Kang, CG Havens, T Conklin, Y Ning, L Wu, T Ito, H Ando, MF Waldman, A Thakurta, A Klippel, H Handa, TO Daniel, PH Schafer, R Chopra |
British Journal of Haematology | 2013 |
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)
EM Ocio, PG Richardson, SV Rajkumar, A Palumbo, MV Mateos, R Orlowski, S Kumar, S Usmani, D Roodman, R Niesvizky, H Einsele, KC Anderson, MA Dimopoulos, H Avet-Loiseau, UH Mellqvist, I Turesson, G Merlini, R Schots, P McCarthy, L Bergsagel, CS Chim, JJ Lahuerta, J Shah, A Reiman, J Mikhael, S Zweegman, S Lonial, R Comenzo, WJ Chng, P Moreau, P Sonneveld, H Ludwig, BG Durie, JF Miguel |
Leukemia | 2013 |
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia
G D'Arena, R Guariglia, FL Rocca, S Trino, V Condelli, LD Martino, VD Feo, P Musto |
Clinical and Developmental Immunology | 2013 |
Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity
N Shah, B Martin-Antonio, H Yang, S Ku, DA Lee, LJ Cooper, WK Decker, S Li, SN Robinson, T Sekine, S Parmar, J Gribben, M Wang, K Rezvani, E Yvon, A Najjar, J Burks, I Kaur, RE Champlin, CM Bollard, EJ Shpall, E Alici |
PloS one | 2013 |
Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype
Göthert JR, Eisele L, Klein-Hitpass L, Weber S, Zesewitz ML, Sellmann L, Röth A, Pircher H, Dührsen U, Dürig J |
Cancer Immunology, Immunotherapy | 2013 |
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
AG Ramsay, AJ Clear, R Fatah, JG Gribben |
Blood | 2012 |
Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC
WK Decker, N Shah, D Xing, R Lapushin, S Li, SN Robinson, H Yang, S Parmar, MM Halpert, MJ Keating, JG Gribben, JJ Molldrem, EJ Shpall, WG Wierda |
PloS one | 2012 |
Immunological aspects in chronic lymphocytic leukemia (CLL) development
R García-Muñoz, VR Galiacho, L Llorente |
Annals of Hematology | 2012 |
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
ES Blix, JM Irish, A Husebekk, J Delabie, L Forfang, AM Tierens, JH Myklebust, A Kolstad |
BMC Cancer | 2012 |
Immune Reconstitution in Chronic Lymphocytic Leukemia
JC Riches, AG Ramsay, JG Gribben |
Current Hematologic Malignancy Reports | 2012 |
T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production
JC Riches, JK Davies, F McClanahan, R Fatah, S Iqbal, S Agrawal, AG Ramsay, JG Gribben |
Blood | 2012 |
Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy
R Weinkove, CR Brooks, JM Carter, IF Hermans, F Ronchese |
Haematologica | 2012 |
Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma
R Martiniani, VD Loreto, CD Sano, A Lombardo, AM Liberati |
Advances in Hematology | 2012 |
Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
JM McDaniel, J Pinilla-Ibarz, PK Epling-Burnette |
Advances in Hematology | 2012 |
Lenalidomide in the Treatment of Chronic Lymphocytic Leukemia
A Cortelezzi, M Sciumè, G Reda |
Advances in Hematology | 2012 |
Immunotherapy of acute myeloid leukemia based on γδ T cells
J Gertner-Dardenne, C Fauriat, N Vey, D Olive |
OncoImmunology | 2012 |
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
A Lopez-Girona, D Mendy, T Ito, K Miller, AK Gandhi, J Kang, S Karasawa, G Carmel, P Jackson, M Abbasian, A Mahmoudi, B Cathers, E Rychak, S Gaidarova, R Chen, PH Schafer, H Handa, TO Daniel, JF Evans, R Chopra |
Leukemia Supplements | 2012 |
Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule
JE Castro, J Melo-Cardenas, M Urquiza, JS Barajas-Gamboa, RS Pakbaz, TJ Kipps |
Cancer research | 2012 |
Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
XC Badoux, MJ Keating, S Wen, WG Wierda, SM O'Brien, S Faderl, R Sargent, JA Burger, A Ferrajoli |
Journal of Clinical Oncology | 2012 |
Lenalidomide Alone and in Combination for Chronic Lymphocytic Leukemia
CI Chen |
Current Hematologic Malignancy Reports | 2012 |
Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia
Fecteau JF, Kipps TJ |
Frontiers in bioscience (Scholar edition) | 2012 |
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease
D Bagnara, MS Kaufman, C Calissano, S Marsilio, PE Patten, R Simone, P Chum, XJ Yan, SL Allen, JE Kolitz, S Baskar, C Rader, H Mellstedt, H Rabbani, A Lee, PK Gregersen, KR Rai, N Chiorazzi |
Blood | 2011 |
Chronic Lymphocytic Leukemia: An Update on Biology and Treatment
JC Riches, AG Ramsay, JG Gribben |
Current Oncology Reports | 2011 |
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines
G Wieërs, N Demotte, D Godelaine, PV der Bruggen |
Cancers | 2011 |
The Etiology of Paraneoplastic Autoimmunity
E Maverakis, H Goodarzi, LN Wehrli, Y Ono, MS Garcia |
Clinical Reviews in Allergy & Immunology | 2011 |
Stem Cell Transplantation for Indolent Lymphoma and Chronic Lymphocytic Leukemia
JG Gribben, C Hosing, DG Maloney |
Biology of Blood and Marrow Transplantation | 2011 |
Immunologic aspects of monoclonal B cell lymphocytosis
MC Lanasa, JB Weinberg |
Immunologic Research | 2011 |
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers
JA Dubovsky, D Wang, JJ Powers, E Berchmans, MA Smith, KL Wright, EM Sotomayor, JA Pinilla-Ibarz |
Leukemia Research | 2011 |
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation
JM McDaniel, JX Zou, W Fulp, DT Chen, AF List, PK Epling-Burnette |
Leukemia | 2011 |
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
M Kalos, BL Levine, DL Porter, S Katz, SA Grupp, A Bagg, CH June |
Science Translational Medicine | 2011 |
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
P Pérez-Galán, M Dreyling, A Wiestner |
Blood | 2011 |
Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach
CS Zent, NE Kay |
Leukemia and Lymphoma | 2011 |
Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (FcμR) in patients with chronic lymphocytic leukemia
FJ Li, Y Kubagawa, MK McCollum, L Wilson, T Motohashi, LF Bertoli, JC Barton, S Barnes, RS Davis, H Kubagawa |
Blood | 2011 |
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
XC Badoux, MJ Keating, S Wen, BN Lee, M Sivina, J Reuben, WG Wierda, SM O'Brien, S Faderl, SM Kornblau, JA Burger, A Ferrajoli |
Blood | 2011 |
Epigenetic repolarization of T lymphocytes from chronic lymphocytic leukemia patients using 5-aza-2′-deoxycytidine
JA Dubovsky, JJ Powers, Y Gao, LF Mariusso, EM Sotomayor, JA Pinilla-Ibarz |
Leukemia Research | 2011 |
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Palma M, Hansson L, Choudhury A, Näsman-Glaser B, Eriksson I, Adamson L, Rossmann E, Widén K, Horváth R, Kokhaei P, Vertuani S, Mellstedt H, Österborg A |
Cancer Immunology, Immunotherapy | 2011 |
Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells
X Liang, EA Moseman, MA Farrar, V Bachanova, DJ Weisdorf, BR Blazar, W Chen |
Blood | 2010 |
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells
RN Damle, C Calissano, N Chiorazzi |
Best Practice & Research Clinical Haematology | 2010 |
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia
M Borge, PR Nannini, JG Galletti, PE Morande, JS Avalos, RF Bezares, M Giordano, R Gamberale |
Haematologica | 2010 |
The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor
M Hudecek, TM Schmitt, S Baskar, MT Lupo-Stanghellini, T Nishida, TN Yamamoto, M Bleakley, CJ Turtle, WC Chang, HA Greisman, B Wood, DG Maloney, MC Jensen, C Rader, SR Riddell |
Blood | 2010 |
Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia
FJ Gassner, L Weiss, R Geisberger, JP Hofbauer, A Egle, TN Hartmann, R Greil, I Tinhofer |
Cancer Immunology, Immunotherapy | 2010 |
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine
AE Foster, FV Okur, E Biagi, A Lu, G Dotti, E Yvon, B Savoldo, G Carrum, MA Goodell, HE Heslop, MK Brenner |
Leukemia | 2010 |
How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes
W Blum |
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program | 2010 |
Dose Escalation of Lenalidomide in Relapsed or Refractory Acute Leukemias
W Blum, RB Klisovic, H Becker, X Yang, DM Rozewski, MA Phelps, R Garzon, A Walker, JC Chandler, SP Whitman, J Curfman, S Liu, L Schaaf, J Mickle, C Kefauver, SM Devine, MR Grever, G Marcucci, JC Byrd |
Journal of Clinical Oncology | 2010 |
Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion
D Xing, AG Ramsay, JG Gribben, WK Decker, JK Burks, M Munsell, S Li, SN Robinson, H Yang, D Steiner, N Shah, JD McMannis, RE Champlin, C Hosing, PA Zweidler-McKay, EJ Shpall, CM Bollard |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2010 |
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia
FT Awan, AJ Johnson, R Lapalombella, W Hu, M Lucas, B Fischer, JC Byrd |
Leukemia and Lymphoma | 2010 |
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
CI Chen, PL Bergsagel, H Paul, W Xu, A Lau, N Dave, V Kukreti, E Wei, C Leung-Hagesteijn, ZH Li, J Brandwein, M Pantoja, J Johnston, S Gibson, T Hernandez, D Spaner, S Trudel |
Journal of Clinical Oncology | 2010 |
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
JA Burger, P Ghia, A Rosenwald, F Caligaris-Cappio |
Blood | 2009 |
Adoptive T-cell therapy for B-cell malignancies
M Hudecek, LD Anderson, T Nishida, SR Riddell |
Expert Review of Hematology | 2009 |
Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia
T Nishida, M Hudecek, A Kostic, M Bleakley, EH Warren, D Maloney, R Storb, SR Riddell |
Clinical cancer research | 2009 |
Molecular and cellular mechanisms of CLL: novel therapeutic approaches
L Pleyer, A Egle, TN Hartmann, R Greil |
Nature Reviews Clinical Oncology | 2009 |
From pathogenesis to treatment of chronic lymphocytic leukaemia
T Zenz, D Mertens, R Küppers, H Döhner, S Stilgenbauer |
Nature Reviews Cancer | 2009 |
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
RL Dieu, DC Taussig, AG Ramsay, R Mitter, F Miraki-Moud, R Fatah, AM Lee, TA Lister, JG Gribben |
Blood | 2009 |
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
R Lapalombella, L Andritsos, Q Liu, SE May, R Browning, LV Pham, KA Blum, W Blum, A Ramanunni, CA Raymond, LL Smith, A Lehman, X Mo, D Jarjoura, CS Chen, R Ford, C Rader, N Muthusamy, AJ Johnson, JC Byrd |
Blood | 2009 |
Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug
AG Ramsay, JG Gribben |
Haematologica | 2009 |
E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
G Gorgun, AG Ramsay, TA Holderried, D Zahrieh, RL Dieu, F Liu, J Quackenbush, CM Croce, JG Gribben |
Proceedings of the National Academy of Sciences | 2009 |
Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy
AG Ramsay, AJ Clear, G Kelly, R Fatah, J Matthews, F Macdougall, TA Lister, AM Lee, M Calaminici, JG Gribben |
Blood | 2009 |
Mechanism of action of lenalidomide in hematological malignancies
V Kotla, S Goel, S Nischal, C Heuck, K Vivek, B Das, A Verma |
Journal of Hematology & Oncology | 2009 |
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
G Aue, N Njuguna, X Tian, S Soto, T Hughes, B Vire, K Keyvanfar, F Gibellini, J Valdez, C Boss, L Samsel, JP McCoy, WH Wilson, S Pittaluga, A Wiestner |
Haematologica | 2009 |
N9986: a phase II trial of thalidomide in patients with relapsed chronic lymphocytic leukemia
NE Kay, TD Shanafelt, TG Call, W Wu, BR Laplant |
Leukemia and Lymphoma | 2009 |
Chronic lymphocytic leukemia: Treatment options for patients with refractory disease
M Motta, WG Wierda, A Ferrajoli |
Cancer | 2009 |
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
R Lapalombella, B Yu, G Triantafillou, Q Liu, JP Butchar, G Lozanski, A Ramanunni, LL Smith, W Blum, L Andritsos, DS Wang, A Lehman, CS Chen, AJ Johnson, G Marcucci, RJ Lee, LJ Lee, S Tridandapani, N Muthusamy, JC Byrd |
Blood | 2008 |
Chronic Lymphocytic Leukemia
N Chiorazzi, KR Rai, M Ferrarini |
New England Journal of Medicine | 2005 |